ROPE ETF Volume Surges 23× as Exxon Mobil Shines

Coastal Compass 100 ETF (ROPE) has seen unusual trading volume, which is 23× higher than its average daily volume.

Among its largest positions, Exxon Mobil faces a supportive backdrop as a Bernstein analyst reiterated a Buy rating with a $195 price target, and political headlines hint that looser U.S. climate regulation could further bolster sentiment toward traditional oil and gas majors. Target, another key holding, drew fresh optimism after Jefferies maintained a Buy rating and set a $140 price target, with the stock carrying a Moderate Buy consensus and upside to analyst targets. Healthcare weight Bristol-Myers Squibb is in focus after launching a long‑term extension Phase 3 study for its pulmonary fibrosis drug Admilparant and receiving multiple Hold‑rated research updates, while Comcast’s shares have been volatile around new small‑business connectivity offerings and strong box-office results, and both U.S. Bancorp and CVS Health gained support from bullish analyst ratings and, in CVS’s case, a sector-wide boost from a better‑than‑expected 2027 Medicare Advantage rate increase.